News
AWH
0.9501
0.00%
0.00
Aspira Womens Health Q3 EPS $(0.13) Up From $(0.23) YoY, Sales $2.305M Miss $6.000M Estimate
Benzinga · 11/14 12:37
Aspira Womens Health Q2 EPS $(0.07) Up From $(0.28) YoY, Sales $2.404M Down From $2.423M YoY
Benzinga · 08/13 10:12
*News On Aspira Women's Health Inc. (AWH) Now Under AWHL
Dow Jones · 04/17 21:08
Based on the provided financial report articles, I generated the title for the article: "Annual Report (Form 10-K) for the fiscal year ended December 31, 2024, of [Company Name] (0000926617)" Please note that the title may not be exact, as the provided text does not contain the company name.
Press release · 04/07 08:52
More
Webull provides a variety of real-time AWH stock news. You can receive the latest news about Aspira Women`s Health Inc through multiple platforms. This information may help you make smarter investment decisions.
About AWH
Aspira Women’s Health Inc., formerly Vermillion, Inc., is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1, Overa and OVA1PLUS risk of malignancy tests for ovarian cancer. The Company also sells a product for genetic testing for specific women’s health diseases, called ASPiRA GenetiX, with a core focus on ovarian cancer. OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor before planned surgery. The Overa is a second-generation biomarker panel intended to maintain its product’s sensitivity while improving specificity. OVA1PLUS is a service offering combining its OVA1 and Overa products, designed to enhance accuracy and reduce false elevations in the intermediate-risk area.